VACCINES AS A LIFEBUOY FOR THE COVID-19 PANDEMIC

Susanna Aghajanyan

nn^bu

COVID-19 <UJU4UnU^h

«

»

DOI: 10.52174/2579-2989_2021_1_5

<^^wpwnbp. u/uiyil*luiuyiuibjnLp, hunJuuluipuiLi, rbquqnpdmpjmb, COVAX dpuiqfrp

CuiJuilluipuiLifr dbLibuipLifrg UbL ipuipti uibg' COVID-19-fr r}bJ Luhilyiuitiq ni uipqjnLhuiilbyi u/uiyi-l(uiuyiuibjnLpbpfr J2uiLinLitti ni huiuyiuiyinLitti fru^u-u/bu nL2uiqpuill dbnppbpiwttibp bb, npnbf hniju bb tbp2tjmJ, np uju Linp&uibuipuip 6qbuiduiirfi l(bp£p Lupnq t ipbuuthb/p ifrbb[: Ujb, frbj ipbiTfr Lnibbbu uinuipfrLiui uiirfiubbpfrb LuJ bnybfruLi nq2 2021 p.-fr pbputgpmJ, huiljuiuuipuiuibu ni.2uiqpuill Llfrbfr: id-b ftbju/bu Liuilluipyibbp ni Lihuiqpuihuipbbp hutJunJui-puiLip, Liu^lud t iJp 2upf qnp&nbbbpfrg: Tpuibgfrg uinuipfrbb LubllyiuibqnLpjuib iffrpngbbpb bt, bpipnp-rp' u/uiyilluiuyiuibjnLp-bpp q[nput[ Libpu/nll Liuinuillui-pb[m b bjmpuiyibfribfrLiuiLiuib ni pu2^frj Juipyiui-hpuillbpbbpp huqpuhupb[m Liupnqmpjmbp, fruLi bppnprp' unlbfri utqpuiyi bpLipbbpft huiJuip u/uiyi-l(uiuyiuibjnLpbpfr huuubb/frmpjmbp:

u

p^bli 2020 p. ul|qphg COVID-19 hwdw^w-pwl! tw^bu t wdpn^g w2^wph^

wnn^w^whwlwl L ^dml^qwg^wj^ hwdwlwpq.bph 4pw L, hw^wlwpwp, ^.bnLu ^ pwl^ mwph «llwnw-^wph» ^wm^wumwljmpbp^ 2nLlw!bpp:

Unn^w^whmpjwl pjnLgblbph ^pw 6l2dwl ^6wg-dw! L plwl^mpjw! Sbpwgdw! hwdwrnhpurnnid, ^wm-^wurnrndp l^wummd t wnn^gw^whwlwl hwdwlwp-q.bph IwjmlmpjwlQ1 l^wq^glbin^ h^^u ^wpwl^ h^-^wl^mpjmllbp^ mwpw&nidp, wjl^bu t[ $hlwluwlw! m dwp^lwj^l nbumpulbph wlhwplh oqrnwqnpSm-dp' ^pwlf hwuw!b[h wj[ pd^lwlw! ^gw-

dmmpjmllbph hwdwp': ^wm^wurnrn^bph pw^wpw-

Urnuwlbw UaU2UL3UL

Simbuwqhsmpjwl pbllwdni.

2003 p. qbpwqwbgmpjwJp lu-lwpsbi t bp^lSh-b (uijdJ' C^SC)' «CwJw2fawphwjfrb sbsbuuqft-LpnLpjmb» JwubwqftsmPJwJp: 2007 p. uyiwgb[ t ifibsbuuqfr-yinLpjwb pbLibuidni.fr qfrsu^wb wuyifr6ub b w2^wsubffr wbgb[ C^ISC dfrgwqqwjfrb ifibsbuuiuib hwpwpbpmpjmbbbpfr wJpfrnbmJ' npufbu uiufruyibbs: CbqfrbwL t 12 qfryiuLiwb ^friwyiubfbbpfr:

Largeron N., Levy P, Wasem J., Bresse X. Role of vaccination in the sustainability of healthcare systems. J Market Access Health Policy. 2015; 3(1):27043.

^mlnLpjml ^bpmpbpjmi npn2ni.^bp ^m-jmglb|hu ^bmnLpjni.llbpp b^wsw^ m-lbl hmlT-bu q.w|nL ^mjrnl U pmpÖpnpml| ^mm^mumnL^bph öpmqpbpn^:

^mm^mumrn^bph t^nhmJm^mpqp äUm^np^rnJ t np^bu 2mhmqpq^n ^n^^-ph, pm^mpm^mlnLpjml, öpmqpbph U hml-pmjhl mnn^2nLRjml hmJm^ni.Jp: U"hm-dmJmlm^, mlmbum^ml, dn^n^pT-mqpm-^ml U unghm[m^ml ^lThplbpp 6l2ni.J bli qnpöm^pmJ mnn^m^mhm^ml hmJm-^mpqbph ^pm U hmlqbglni.J ^b^m^-gnglbph qlmhmmJml ^^us plpmgm-^mpqbph:

bp^plbpp цwm4wumwlJmpbp^ qlJml qnpöplpmgl ^pm^mlmglmJ bl mmppbp ÖUbpn^: Hpn2 bp^plbprnJ, hJmlhqmghm-jh mqqmjhl öpmqpbph 2p2mlm^ni.J, ^ms-^murnmljmpbp qlni.J bl ^wnw4wpmpJml-lbpp, JjmulbpmJ1 m^mhn^mqpnqlbpp, mnn^m^mhm^ml 0mnmjni.pjni.ll bp Jm-mni.gn^lbpp ^mJ, lnijlhu^, mlhmmlbpp: ^mm^mummljnLpbph qlJml qnpöplpm-gp ^mhmlgmJ t hmmni.^ plpmgm^mpq, npp mmppbp^nLJ t T-b^bp^ U mj[ ^b^m-qnpöm^ml m^pmlplbph qlm^g2: CIt npmJ, Tpmlg qlbpp npn2^ni-J bl qlrn^b-ph ^mnni.gm^mpqh hmJmÖmjl: U~hmulm-^ml qlrn^bph ^mpmqmjmJ qlbpp hm-m^bLh gmöp bl [^lmJ: L2blf, np 28-hg 21 ujwmi(wumwljnL|afi r|.buj£ni.d lijiiuu-

lm^ml qlrn^bpp hmlqbgpb bl qlhgbg-Jml: ^^mdmJmlm^, qlrn^bph npn2 pl-pmgm^mpqbph hbmUmlpn^ bp^plbpp ^6mpb[ bl qpbpb 2 mlqmJ 2ms qni.Jmp, fml UNICEF-h m ^mm^mumrn^bph U hJnLlhqmghmjh q|npm[ Tm2hlfh ^2ngn^ Öbnp pbpb[hu:

2019 p. ^mm^mummljnLpbph hmJm2-^mphmj^l 2nL^mjh öm^mLp t Jnm

5,5 Jlpt Tb^m^m^ (mnmlg qpnum2pgmjhl U nmqJm^ml 2m^mlbp^)1 33 ^[hmpT U^L TnLmp mpdbpn^, npl plT-hmlrnp T-b-^mqnpöm^ml 2nL^mjh Jnm 2%-l t: PmpÖp b^mJmm nilbgn^ bp^plbp^l pmdhl t pl^-lmJ hmJm2^mphmj^l 2ni^mjh 68%-p: <m-pm^mpUbLjml Uuhmjh U U^ph^mjh mm-pmöm2p2mllbpp 2mpnLlm^ni.J bl цws4wuswlJmpbp^ ^n2npmqmjl qlnpT-lbp, plT npmJ, <lT^mumml^l pmdhl t pl^lrnJ mmpmöm2p2ml^ qlrn^bph Jnm 80%-p3:

^mm^mummljnLpbph mpmmTpnLpjni.-lp ^blmpnlmg^mö t ^npu ^n2np mpmmT-pnqlbph (GSK, Pfizer, Merck, Sanofi) Öbn-fmJ: 4bp2hllbpu ^bpmhu^mJ bl ^mm-^mummljnLpbph hmJm2^mphmj^l 2ni^m-jh 90%-p, huL| SII, GSK, Sanofi, BBIL, Haff-kine pl^bpmpjmllbpp1 ^mm^mummljm-pbph hmJm2^mphmjhl mpmmTp^pjml 60%-p4 (qöm^mm^bp 1):

LbpljUJjnLJ qluj[ni| Lul|mfii|ujlnLJ bl ii|i-

F'FIZER

MERCK

SANOFI

SII

GLAXOSMITHKLINE q-ÖU^USMbP 1

Upmmq.pn^hbp^ mbum^mpmp Qus ^mm^mummhjnL^bp^

U3L

European Vaccine Manufacturers. EVM Reply to the Green Paper on the modernization of EU public procurement policy -Towards a more efficient European Procurement Market, 2012, https:// www.vaccineseurope.eu/wp-content/uploads/2012/12/ EVM-ReplyEC-consultation-procurement-fin.pdf. Published 2012. Accessed May 20, 2020.

Global Vaccine Market Report, 2020, https://apps.who.int/iris/bitstream/handle/10665/311278/WH0-IVB-19.03-eng.pdf7se-quence=1&isAllowed=y

2hl mprnm^pn^lbpp (hh^m^mlmd' UuhmjnLd), npnlf pl^wjlnLd bl hP^^g mp-rnm^pm^ml ^nprn$b[lbpp (HPV U PCV), dpgm^gmd ^mrn^murnmljnLpbph smpm-Sm2p2mlmjhl U lnp ^nrn-

2mp^b[n^ [pmgni.gh£ U hmóm^ 2ms m^bLh dmrn^h rnmppbpm^lbp:

<brnmqnrnni.pjni.ll bp p ^mm^mumm-ljnipbph d2m^dml hh^mpmpl bl' rnqq^mS mnn^m^mhnLpjml lbp^m dmpsmhpm-^bplbph hm^pmhmpdmlp, hl^bu lmU hbsmqm u^mnlm[hflbphl mpómqml-^mm^wurnmljnLpbph d2m^dmli qnpSplpmgp ^mpn^ t sUb[ rnmulmdjm^-lbp' u^umS ^l^U lm^m^hlh-

^m^ml U ^Lhlh^m^ml ^npómp^rn^bp, ^bpgmgpmó ^pmlg ml^rnmlqnLpjml, mp-^.jmlm^bmmpjml 2mpni.lm^m^ml d2sm-^smp^dmdp U qlmhmmdmdp: HpUt ^mm^mummljmph d2m^dml qnpSplpm-gp ^mpn^ t sUb[ 15-20 mmph, hu^ mpdbpp ^mpn^ t mmmml^bL 200-800 ^[hnl b^pn-jh 2p2mlm^md6: Upmm^pmpjml mUn^m-pjmlp ^ fmlh mduhg ^l^U bpbf mmph t, pl^. nprnd, bpb npm^h ^.bpmhu^dml hl¿-np ^nq Óm^nq4nLd t, qnpSplpmgp u^u^md t lnphg7:

Um^mjl, hmdm^mpm^h pnl^mdp hml-qbgpbL t lpml, np ^mm^mummljmpbph qpmlgmd ^mpb[h t ^mrnmpb[ mpsmhbpp nbd^dn^, hl^h mp^jmlfmd 2021 p. u^qphl m2^mphmd mp^bl d2w^4nLd t dnm 200 ^mm^mummljmp, nphg 6-l mp^bl ^h-

pmn^md t plw^nLpjml ^mrn^wurndmli l^mmm^n^8:

BioNTech-h U Pfizer-h qnp&pl^bpni.-pjml mp^.jmlfmd urnbq&^wS COVID-19-h ^mm^mummljmpbpp (Pfizer/BioNTech) U Moderna-l mprnm^mpq oqsmqnpSdml pnLjLm^nLpjnLl bl ummgbL Mmlm^mj md, b^pm^mpjmlmd, ^hmgjm[ famqm^npni.-pjmlmd, U"hmgjm[ Lmhmlqlbpmd U mj[ bp^plbpmd: 4mpm^dml nhu^h qnmm 2ms m2^mrnn^lbp U plm^nLpjml mnm^b[ ^ngbih hmrn^mSlbp usmgb[ bl mnm2hl ^m^mpmdhllbpp: Ujl ^murnp, np SARS-CoV-2 ^mrn^murnmljmpbph mnm2hl qnp-Smpflbphg ^^p ^lf^bL t m2^mphh m^-lmhmpmurn bp^plbph U hmdm2^mphm-jhl ^n2npmqmjl ^.bqmqnp&m^ml pl^b-pmpjmllbph ^2U, ^^mjrnd t T-pmlg d2m^-dml U mprnm^pmpjml ^2 mn^m $hlml-um^ml ^mpbph dmuhl (mqjnwm^ 1):

AstraZeneca-h ^mrn^murnmljmph qlmd-lbph 2mp2 40%-p ^md dns 2,4 d[p^. ^b-qm^m^ pmdhl t pl^lnid ^2hl U gmSp b^mdnis rnlbgnq bp^plbphl, ^l^bn ^bp-2hlhu ^2hl mpq.jmlm^brnmpjmlp 70% t' Pfizer/Biontech-h 95% mp^jmlm^brnmpjml ^hdmg: Bloomberg-h ^hsmp^dmdp' ldml ^mhml2mp^p ^mjdmlm^np^mS t mj^

^mrn^murnmljmph dmrn^b[h^pjmdp:

Sputnik V ^mrn^murnmljmpl mp^bl qpmlg^b[ t m2^mphh 26 bp^pmd: Rl^w-^h lbp^pm^bph nmum^ml hh^m^pmdp ^hlmlum^npmd t ^mumummlmd Alium

ua3^uuM 1

COVID-19 ^mm^mummhjm^bp^ hm^JmmmJ9

y

Pfizer/Bí ontech X* 3-70C 20

AstraZeneca l_lLLIn.'uLLIpLLI'LJLUJ[YÜ ^hp^LuumfiSiuij 4

Moderna /2 S -20C 33

Sputnik V /a l_lLLIn.'ULLIpLLltl LLIj[l Ü ^hp^LLJULnh^1^^ 10

7 Plotkin S., Robinson JM, Cunningham G., Iqbal R., Larsen S., The complexity and cost of vaccine manufacturing—an overview. Vaccine, 2017, 35(33):4064-4071.

8 https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines

9 https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines

DynavHx/Valvena Clover/Gla>o Si novae Cure vac Sputnik V Modern a Pfizer/Bio nTech San ofi,■'Glaxo

J&J Novavax Astra Zeneca

200

400

600

800

1000

¡200

1400

■ bi[pniijm ■ ULJL ■ LAjwgw& bpLiptibpp

q-tju^usMbn 2

^wm^wumwfojnLpbp^ pw2^ni.^ pus bp^pfabp^ (d[h

^Jph Jmln^ ^npm^bimjhl pl^bpni.-pjnLllbph mpmm^.pm^ml hqnpni.pjni.llb-pp' hmJmqnp&m^gbin^ U qmlq^m&mjhl mpmm^.pni.pjni.l ¿m^mi^n^ mb^m^mtl lbp^.pni.Jmjhl hh^m^.pm^bph hbm, mj^ p4nLJ' ^ln^mummlnLJ, <mpm^mj^h Mn-pbmjrnJ, Ppmq^ihmjmJ, QhlmummlmJ, Umni4jml Upmp^mjmJ U ^mpf^mjmJ (q&m^mm^bp 2):

Ujhmm^hmjhh^, COVID-19-h wti^mwtiq U mp^jmlm^bm ^mm^mummljnLpbph nL mpmm^pmpjmll ml^mum-^bihnpbl m^b^g^bim bl ^^ wjl ^d^mpm-pjmJp. hwJw2^wphwj^l ^mhmlgmp^h Sm^milbpp qbpmqmlgbim bl Jmmm^m-pmpJml hlmpm^npnLpjnillbpp: Unmlg qinpmi ^m^mpmd^llbp^ pm2^Jml pmq-Jm^n^J hmJmSmjImpjmllbp^i mpsm^pp-Jml U pm2^Jml qnpSplpmglbph ^mq-Jm^bp^Jml ^mpn^ bl mnmgmlmi Lpmgmg^^ pmp^mpjmllbp, npnlg hb-mUmlfn^ 2mhmqpq^n ^n^^pp ^mlq-lbl ^^ mji Jmpmmhpm^bph mngU. ^l^-^bu mprnm^pbi U pm2^b pm^mpmp npm^h U pmlm^h ^mm^mummljmpbp hmJm2^mphmj^l ^mhmlgmp^p pm^m-pmpbim hmJmp:

Cum Airfinity pl^bpmpjml m^jmilbph'

U^L-p hlmpm^npmpjml ni.lh mprnm^pb-Lm COVID-19-h ^mm^mummljnLph qpbpb 4,7 ^ihmp^ ^b^m^m^' ^l^U 2021-h ^bp-2p, ^mdmJmlm^, Deutsche Welle-h hpm-^mpm^mS mp^jnLlplbpp ^^mjmJ bl, np <l^mummlp lnijl^bu mju mnmJn^ m-nmgmmmp t U ^mpn^ t m^mhn^b m^bih fml 3 ^ihwpT- ^b^m^m^" (q&m^mm^bp 3):

L2blf lmU, np m2^mphmJ ^mm^mu-mmljnLpbph ^n2npmqmjl mprnm^pn^ t <l^mummlh 2h^nL^mjhl ^lum^mmmp, npmb^ tl hblg AstraZeneca-l lm^mmbumJ t mprnm^pbi «University of Oxford» tdml

^mm^mummljnLph m^bih fml 1 Jip^ ^b-

^m^m^:

hl^bu gnLjg t mmihu ^h^m^mqpm-pjmlp, gmSp U b^mJmm nilbgn^

bp^plbpp ^m^^mS bl ^^mgjmi famqm-^npmpjml^g' Astra Zeneca-h ^mm^mu-mmljmpp qlbini. hJmumn^:

Unn^m^mhnLpjml hmJm2^mphm-jhl ^mqJm^bp^mpjml COVAX Spmqhpp 2021 p.-h plpmgpmJ ^l^mum^ ^mm^mu-mmljnLpbph bp^ni. ^ihmp^ ^b^m^m^^ pm2^Jmlp Jnm 190 Jmulm^g bp^plbp^' ml^m^ lpmlg ^mp^m mlm^mpjml^g: ^mumnpbl, ^bmf t ih^bl pm^mpmp ^m-

10 https://www.bloomberg.com/news/articles/2020-11-22/astra-oxford-shot-is-key-to-escaping-pandemic-for-many-nations " https://www.statista.com/chart;/23885/coronavirus-vaccine-production-capabilities-by-country/

U\ ^mqm^npmpjrnb

<4. ^npbm

Я-Ш'ПЦ.ЗЧЬП 3

^npn^^hpnLuh щшm4шumшfajnl.ph шpmш^pш^шb ^шpnqnLpJnЛUЬpU qus Ьp^pfaЬph (dpq цЬцшшФ)2

фшpшd^llЬp, 2021 p.-h ^huhphl шdpn^2 ш2^шphmJ шnn^2шщшhш^шl U ung^-|ш^ш1 ш2^шmnrç!hphl щш2т-

hшJшp: Urnh^ô^hL t фшulш^шl qlrn^hph hшppш^, npQ hшJш^шpqmü hl ф2шqqшJ^l qnpÔQl^hplhpQ1 COVAX FACILTY hh^шrç.pшф ^gngn^: ^hpg^lu pшlш^gmpJmllhp t ^prnd щшm4шumшlJnLphph шpmшrç.pnrç!hph hhm1 lщшumh|n4 qnpÖQlpшgh шpшqшg-^Iq, uшhdшlh|n4 фшulш^шl qlhp, hh^шrç.pшdnLd Qlrçqp^^ô hp^plhph hшdшp hpш2^ш4np4шö qln^ U £ш1ш^п^ цшm4шumшlJmphp^ Öhnpphp-dшlQ:

« шnn^2шцшhmpJшl lш^шpшpnL-pjmlQ COVAX FACILTY-h Ьф^ш^шф hhs urnnpmqph[ t hшJшÖшJlшqhp, COVID-19-h rç.hd цшm4шumшlJmph Öhn£phpdшl hш-Jшp: Lrn^rnmhu^nLd t qlh[ 2пФ2 600 hrn-qшp ^^ш^шф1 nhu^h ^dphpmd qml^n^ 2mp2 300 hшqшp ш!0Ь hrndrnp (jm^-^lymphl hp^ni. ^^ш^шф): ^rnm^rnu-mшlJmph Öhn£phpdшl Qlrç.hшlnLp шpdh-fQ Jnmш4npшцhu 6 ^Lhnl 330 hrnqrnp UUL rç.n|up t, ^^ п^ш^шфЬ ^2h^g-^шб шpdhfQ, 10.55 UUL n.n|up, npQ ^ш-pn^ t pшlш^gmpJmllhph шp^.Jmlfmü l^qh^:

COVAX FACILTY ôprnqph 2P2шlшl|nLd

fl^p^^L hl COVID-19-h щшm4шumш-Ijmphph ÖhnfphpJшl hlшpш4npmpJml-IhpQ U npn2^h[ Нш^шщштшу^ш! щшт-^rnumnL^hpl hpш^шlшglhL фпцш^! h^u^^n^ nhul^jhl ^Jphph hшJшp uшhdшlh|n4 шnш2lшhhppmpJmllhp, hh-тЦ|ш[ hш2np^ш^шlmpJшJp.

• 1-hl фпц. mrnphglhph ^^dfh ^hlm-pnllhph p^^lhp U ш2^шmш^hg-Ihp, pmdш2^шmn^lhp, ung^iu^l

^ilrndph ^hlmpnllhph ш2^шmш^hg-Ihp, 65 U шфф pшpöp mшphfh ш1-Öhlf, 16-64 mшph^шl hh^lrçlhp,

• 2-prç. фпц. rç.шuш^nulhp, mumgh^lhp, rnpmrn^rnpq hpшфóш^lhph 1ш^ш-pшpmpJшl ш2^шmш^hglhp, qhlôrn-nujnrçlhp, up^^u^um^^! n|npmh ш2^шmш^hglhp, hrnlprnjhl mpшlu-^npmh ш2^шmш^hglhp, ^тш^ш! örnnrnjn^lhp™:

COVAX FACILTY ^^^h^mp^l 2Qp-2ш!ш^шЛ <шJшumшlhl шnш2шp^4hL t AstraZeneca Ql^hpnLpjrnl щшm4шumш-Ijmph ÖhnfphpJшl hlшpш4npmpJml, Irn^rnmhu^rnö p^^mp^l 3%-h hш-Jшp, hlшpш4nphlu ^ш^

drnd^hrnrnd hшuшlhLhnLpJnl!Q (2021 p. Jшpm) U rnpdhfh Jшm¿h[h^pJ^lQ:

hl^hu mhulmd hlf, ^пшш^ш drn-

'2 https '3 https '4 https

//www.statista.com/chart/23885/coronavirus-vaccine-production-capabiiities-by-country/

//www.moh.am/#1/3201

//www.moh.am/#1/3501

ииъ

^Ьш^ЬЬршЛ mbqf Ьр^т. hш-

^ш^шрй ц.пр0р1ршд1Ьр. COVID 19-f l^rn^dp рЬш^п^шЬ fdni^j fil шq-^.ш^Ьр! nLdbrçmgnLd U щшт^шитш-

iНе можете найти то, что вам нужно? Попробуйте сервис подбора литературы.

иш ^шЬш^шЛ t, пр ш^ «^прЬрр» Jnm шщшqшJnLd «^Ишт^Ы», U, 2^прИ14 щшт-4шитш1|П1.рЬр1, hшdш4шрш^l шит^-бш^шршр ^^ш шЬд]ш|П|Л:

o^su^nptt^utt ч^ичиъпьшпьъ

European Vaccine Manufacturers. EVM Reply to the Green Paper on the modernization of EU public procurement policy - Towards a more efficient European Procurement Market, 2012,

https:// www.vaccineseurope.eu/wp-content/up-loads/2012/12/EVM-ReplyEC-consultation-procure-ment-fin.pdf. Published 2012. Accessed May 20, 2020.

Global Vaccine Market Report, 2020, https://apps.who.int/iris/bitstream/han-dle/10665/311278/WH0-IVB-19.03-eng.pdf?se-quence=1&isAllowed=y

International Federation of Pharmaceutical Manufacturers & Associations.Vaccine research and development. https://www. ifpma.org/resource-centre/vaccine-re-search-and-development/. Accessed May 20, 2020.

4. Largeron N., Lévy P., Wasem J., Bresse X., Role of vaccination in the sustainability of healthcare systems. J Market Access Health Policy. 2015;3(1):27043.

5. Plotkin S., Robinson JM, Cunningham G., Iqbal R., Larsen S., The complexity and cost of vaccine manufacturing—an overview. Vaccine. 2017;35(33):4064-4071.

6. https://www.who.int/emergencies/diseases/nov-el-coronavirus-2019/covid-19-vaccines

7. https://www.bloomberg.com/news/arti-cles/2020-11-22/astra-oxford-shot-is-key-to-escap-ing-pandemic-for-many-nations

8. https://www.statista.com/chart/23885/coronavi-rus-vaccine-production-capabilities-by-country/

9. https://www.moh.am/#1/3201

10. https://www.moh.am/#1/3501

Сусанна АГАДЖАНЯН

Кандидат экономических наук, АГЭУ

ТРАЕКТОРИЯ ПАНДЕМИИ

ВАКЦИНЫ КАК «СПАСАТЕЛЬНЫЙ КРУГ» ОТ СОУЮ-19

Спустя год после вспышки эпидемии разработка и валидация безопасных и эффективных вакцин против С0УЮ-19 стали поистине выдающимися достижениями, вселяющими надежду на то, что конец этого разрушительного кризиса может быть близок. События ближайших месяцев или даже всего 2021 года будут однозначно важными. Как мы остановим и преодолеем пандемию, зависит от ряда факторов. Первый фактор - это меры безопасности, второй фактор - способность в глобальном масштабе управлять вакцинами для решения логистических и распределительных задач,и третий - доступность вакцин для более бедных стран.

Ключевые слова: вакцина, эпидемия, фармацевтика, программа COVAX

Susanna AGHAJANYAN

PhD in Economics, ASUE

PANDEMIC TRAJECTORY

VACCINES AS A LIFEBUOY FOR THE COVID-19 PANDEMIC

A year after COVID-19 began, the development and validation of safe and effective vaccines against it will lead to a major breakthrough. The events of the upcoming months or even of the whole 2021 will be significantly important. How we survive and overcome the epidemic depend on a number of factors. The first are security measures. The second factor is the ability to manage vaccines on a global scale to solve logistical and distributional issues. And, thirdly, the availability of the vaccine for the developing countries.

Key words: vaccine, epidemic, pharmaceuticals, COVAX program

VACCINES AS A LIFEBUOY FOR THE COVID-19 PANDEMIC Текст научной статьи по специальности «Экономика и бизнес»

Аннотация научной статьи по экономике и бизнесу, автор научной работы — Susanna Aghajanyan

Похожие темы научных работ по экономике и бизнесу , автор научной работы — Susanna Aghajanyan

ВАКЦИНЫ КАК «СПАСАТЕЛЬНЫЙ КРУГ» ОТ COVID-19

Текст научной работы на тему «VACCINES AS A LIFEBUOY FOR THE COVID-19 PANDEMIC»